SKP2 and non-small cell lung carcinoma: On the one hand, knockout of SKP2 significantly increased the sensitivity of Her2 positive breast cancer cells to Herceptin [15], on the other hand, SKP2 silencing or inactivation can restore non-small cell lung cancer sensitivity to gefitinib treatment [16].